Sunday, January 12, 2014

Living with parkinsons

This is a personal recount from a neurologist and how he found out that he had parkinsons disease.



Saturday, January 11, 2014

Parkinson's disease and dopamines role

          Parkinson’s disease is a liberal neurological disorder which affects the motor system and thus individual’s ability to move. It is caused by the slow progressive degradation of neurons due to either genetic or environmental effects and the lack of dopamine in the substantia nigra of the brain. Dopamine is a neurotransmitter essential for the transfer of neuronal signals from the brain to the spinal cord and eventually to the appropriate muscles in the body. The shortage of dopamine in patients suffering Parkinson’s disease thus leads to the impairment of their muscular function. 

           Dopamine is produced from the conversion of L-tyrosine through the intermediate product dihydroxyphenylalanaine (L-DOPA) in step-wise process catalyzed by specific enzymes. This process occurs in the dopaminergic neurons of substantia nigra.
The following shows the complete 2-step reactions of dopamine production.
1)    Catalysed by tyrosine 3-monooxgenase
L-tyrosine + THFA  + O2 + Fe2+ L-dopa + DHFA + H2O + Fe2+
2)    Catalysed by dopa decarboxylase
L-dopa + pyridoxal phosphate dopamine + pyridoxal phosphate + CO2


           Any deficiencies of the substrates required for L-dopa formation such as L-tyrosine, iron and THFA (tetrahydrofolic acid) or for dopamine formation (from L-dopa) such as pyridoxal phosphate will lower the enzymes’ activity. This is evident in individuals with Parkinson’s disease in which the activity of either tyrosine 3-monooxgenase or dopa decarboxylase are as low as 20% (or less).The lack of one or more of the substrates also contributes to the damage of dopaminergic neurons by highly toxic superoxide anion produced by the resulting faulty reaction. 

Signs of parkinson's

           Excessive and unconscionable muscle contractions are usually the initial symptoms of Parkinson’s disease. They develop as the activity of dopaminergic neurons decreases. Also, the symptoms and their severity differ from patient to patient.


Typical symptoms include:

o   Tremor; Most apparent symptom and occurs in various parts of the body, most commonly in the hand and fingers. May be diminished when rigidity (another symptom) becomes severe.

o   Rigidity; stiffness and constraint in the muscles leading to pain in rigid areas as the continual contraction of the muscles proceeds.

o   Hypokinesia; Difficulty to make movements especially small movements (due to the reduced muscle movement in the limbs, one side or the whole of the body) with the occurrence of pauses. Other stages include Bradykinesia when muscles react slowly, hence slower movements and akinesia when there is a loss of movement. Hyphophonia is another symptom whereby the individual has soft voice due to the lack of coordination of the vocal muscles.

o   Flexion of trunk; affecting and reducing the motility of muscles around the oesophagus (spasms), small intestine, and stomach results in constipation. In severe condition, posture of the body may be disturbed such as the neck and shoulder are bent at a right angle respective to the trunk. Festination occurs overtime.

o   Urinary incontinence; loss control of urogenital muscles and only develops in later stage of Parkinson’s disease. May lead to incompetence

o   Lewy bodies; aggregation of protein inside neurons which indicates cellular damage is occurring. Besides Parkinson’s disease, Lewy bodies are also associated with dementia and other disorders.

Other disorders such as depression, dementia, dystonia, and sleep disturbances may also develop together with Parkinson’s disease.

Aldehyde dehydrogenase as neuronal protection

                 2 known isoenzymes of Aldehyde dehydrogenase (ALDH), ALDH 1A1 and ALDH 2, are found to have the crucial role for metabolizing toxic amine-related aldehydes and superoxides, to prevent the destruction of neurons.



                  Although little is known about their role in Parkinson’s disease however recent studies conducted show that there are alterations of ALDH 1A1expression in the brain (substantia nigra) of individuals with Parkinson’s disease. The level of activity of ALDH 2 was also found to be abnormal in patients suffering the disease. Scientists are currently doing more research on the basis of the unusual ALDH activity in patients with Parkinson’s disease in hope that it could become the solution for improved and more accurate diagnosis of the disease. 

How can we treat parkinsons?

                  There are currently no cures for the loss of neurons in individuals with Parkinson’s disease. Treatments are available only for the symptoms of the disease.

                   Combination of the drug Levodopa (L-dopa) with carbidopa is the most efficient treatment that helps increase the conversion of L-dopa into dopamine in the brain while minimising the side effects of Levodopa such as nausea. Such drug treatment could last within 4 to 6 years as the effects of the drug will begin to subside (ie. Drug dose becomes effective for shorter period of time that gradually wears off). Symptoms of the disease such as tremor, muscle spasms of the neck, eyes and jaw would then reappear again. Patients may choose to increase the dosage of the drug however this comes with risky effects of dyskinesia.

Alternative drugs include:
·         Dopamine agonists – “imitates” the action of dopamine in neurons of the brain. Although they are not as efficient as levodopa, they do not wear off easily and last longer in the brain.

·         MAO B (Monoamine Oxidase B) inhibitors- Prevent the breakdown of dopamine in brain caused by MAO B to slow down the loss of the neurotransmitter. Side effect are in most cases are mild

·         Amantadine- Alleviate the effects of dyskinesia and early mild symptoms of Parkinson’s disease. Usually prescribed together with Levodopa-carbidopa.
                   Another costly method is through a surgical procedure known as deep brain stimulation (DBS). Electrodes are implanted within the body of the patient and are connected with the generator in the chest. This allows electrical signals to reach the brain and prevents the occurrence of the symptoms. DBS is usually conducted to patients suffering from the later stages of Parkinson’s disease (levodopa is no longer effective).





Fun Facts!

Find out if you have parkinsons with a phone call!


Famous people with parkinsons disease!


( P.S. if you are using an ad blocker, you will have to turn it off temporarily)